Dr. Peter Rahl, Ph.D., joined Kronos Bio in March 2020, and serves as Vice President, Discovery Biology. Pete’s primary responsibilities are to lead the preclinical drug discovery portfolio through integrating functional areas needed to develop clinical candidates.

Pete is a molecular biologist with expertise at the interface of genomics, chemical biology and drug discovery. Before his tenure at Kronos Bio, Pete helped multiple start-up companies grow from company concepts into clinical-stage, publicly traded companies ($SYRS, $FULC and now $KRON). While at these companies, he was involved in discovering multiple clinical candidates, including Pociredir, a novel EED ligand, for fetal hemoglobin reactivation in Sickle Cell Disease from target identification and screening to development candidate nomination.

Pete has made important scientific contributions understanding how to modulate gene regulation and chromatin structure for therapeutic purposes. His experience in drug discovery and genomics have allowed him and his teams to understand drug mechanism of action at a molecular level to guide how best to use certain classes of molecules.

Pete received his Ph.D. in pharmacology from Cornell University, where he trained with Dr. Ruth Collins. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research, with training in Dr. Richard Young’s laboratory.